PHARMACEUTICAL IP

  • Offering
    • Evolve AI
      • Albert (Validity)
        • Validity analysis
        • Albert Construe (Claim construction)
      • Popper (Prosecution)
      • Franklin (Publication review)
      • AI for Sequences
    • Fractional IP counsel
    • Services
      • AI guidance
      • Competitive intelligence
      • Deals
      • Due diligence
      • Freedom to operate
      • IP strategy and communication
      • Oppositions and appeals
      • Patent drafting
      • Patent prosecution
      • Trade secrets
    • Technologies
      • Pharmaceuticals
      • Biologics
      • Cell & gene therapy
      • AI drug discovery
    • Our clients
      • Biotech
      • CROs and CMOs
      • Established pharma
      • International IP counsel
      • Investors
      • Start-ups
      • Universities
  • Fractional IP counsel
    • Fractional IP counsel
    • What is fractional IP counsel?
    • Our clients
      • Biotech
      • CROs and CMOs
      • Established pharma
      • International IP counsel
      • Investors
      • Start-ups
      • Universities
  • Evolve AI
    • Albert (Validity)
      • Validity analysis
      • Albert Construe (Claim construction)
    • Popper (Prosecution)
    • Franklin (Publication review)
    • AI for Sequences
  • Technologies
    • Pharmaceuticals
      • Dosing regimens
      • Formulations
      • Life cycle management
      • New indications
      • Platform technologies
    • Biologics
      • Antibodies
      • Antibody-drug conjugates (ADCs)
      • T cell engagers (TCEs)
    • Cell & gene therapy
      • CAR-T cell therapies
      • Gene therapies
      • In vivo CAR-T
      • Lipid nanoparticles (LNPs)
      • Macrophages (CAR-M)
      • mRNA therapeutics
      • Regenerative cell therapies
    • AI drug discovery
  • Insights
    • Articles
    • Pharma IP Toolkit
    • Evolve Guides
    • Events & Webinars
    • Subscribe
  • About us
    • Our team
    • Recognition
    • Join us
    • Contact us
  • Offering
    • Evolve AI
      • Albert (Validity)
        • Validity analysis
        • Albert Construe (Claim construction)
      • Popper (Prosecution)
      • Franklin (Publication review)
      • AI for Sequences
    • Fractional IP counsel
    • Services
      • AI guidance
      • Competitive intelligence
      • Deals
      • Due diligence
      • Freedom to operate
      • IP strategy and communication
      • Oppositions and appeals
      • Patent drafting
      • Patent prosecution
      • Trade secrets
    • Technologies
      • Pharmaceuticals
      • Biologics
      • Cell & gene therapy
      • AI drug discovery
    • Our clients
      • Biotech
      • CROs and CMOs
      • Established pharma
      • International IP counsel
      • Investors
      • Start-ups
      • Universities
  • Fractional IP counsel
    • Fractional IP counsel
    • What is fractional IP counsel?
    • Our clients
      • Biotech
      • CROs and CMOs
      • Established pharma
      • International IP counsel
      • Investors
      • Start-ups
      • Universities
  • Evolve AI
    • Albert (Validity)
      • Validity analysis
      • Albert Construe (Claim construction)
    • Popper (Prosecution)
    • Franklin (Publication review)
    • AI for Sequences
  • Technologies
    • Pharmaceuticals
      • Dosing regimens
      • Formulations
      • Life cycle management
      • New indications
      • Platform technologies
    • Biologics
      • Antibodies
      • Antibody-drug conjugates (ADCs)
      • T cell engagers (TCEs)
    • Cell & gene therapy
      • CAR-T cell therapies
      • Gene therapies
      • In vivo CAR-T
      • Lipid nanoparticles (LNPs)
      • Macrophages (CAR-M)
      • mRNA therapeutics
      • Regenerative cell therapies
    • AI drug discovery
  • Insights
    • Articles
    • Pharma IP Toolkit
    • Evolve Guides
    • Events & Webinars
    • Subscribe
  • About us
    • Our team
    • Recognition
    • Join us
    • Contact us
  • Offering
  • What is fractional IP counsel?
  • Evolve AI
  • Technologies
  • Insights
  • Our team
  • Offering
  • What is fractional IP counsel?
  • Evolve AI
  • Technologies
  • Insights
  • Our team

Biotechnology

The biotech landscape demands an adaptable IP strategy that can respond to rapid scientific advances and evolving legal frameworks. At Evolve, we specialise in crafting robust IP strategies for biotech innovations, from novel therapeutic modalities to breakthrough research tools.

We understand the unique challenges biotech companies face, including platform protection considerations, competitive landscapes, and investor expectations. Our expertise helps you navigate complex IP decisions while building value-creating patent portfolios tailored to your specific technology and commercial objectives.

Technology insights...

Gold band splitting into three branches at a turquoise junction on dark blue, Evolve abstract article image
Gold band splitting into three branches at a turquoise junction on dark blue, Evolve abstract article image

Fractional IP counsel for biotech: what to look for in a fractional IP adviser

  • 16th November 2026
What to look for in part-time senior IP support for a growing biotech, from Series A to partnering and acquisition, and how experienced fractional IP counsel can help at every stage.
Twisting strand of gold beads with a turquoise section on dark blue, Evolve biotechnology image
Twisting strand of gold beads with a turquoise section on dark blue, Evolve biotechnology image

AI for patent sequences: Avoiding costly sequence errors

  • 6th November 2026
A single wrong residue can mean a patent does not cover the product. Evolve’s AI Sequence Agents build ST.26 listings in code, check every residue, keep the claims covering the lead in line with the IP strategy from drafting to grant, and check the sequences in granted patents.
Pyramid of gold spheres with a turquoise apex and pink equator line on dark blue, Evolve Franklin image
Pyramid of gold spheres with a turquoise apex and pink equator line on dark blue, Evolve Franklin image

Franklin: AI-powered publication review for pharma

  • 23rd October 2026
Publication screening is a time sink for pharma patent attorneys. Franklin quickly finds the undisclosed inventions in a new publication submission.
Turquoise sphere held in gold gyroscope rings with a pink edge line on dark blue, Evolve Albert image
Turquoise sphere held in gold gyroscope rings with a pink edge line on dark blue, Evolve Albert image

Albert: AI-powered competitive intelligence and IP validity analysis for biotech & pharma

  • 23rd June 2026
Expert analysis based on deep industry expertise, delivered quickly and cost-effectively.
Gold ball-and-stick molecule with one turquoise atom on dark blue, Evolve pharmaceuticals image
Gold ball-and-stick molecule with one turquoise atom on dark blue, Evolve pharmaceuticals image

EPO pharma case law trends 2025: Clinical inventions

  • 26th November 2025
The law in the pharma sector is also constantly evolving. Understanding the case law trends when drafting, prosecuting and defending these cases is therefore paramount. In our second post on EPO pharma case law trends in 2025, we review the most impactful decisions of the year relating to clinical-stage inventions. 
Stack of gold plates fanning open around a turquoise light on dark blue, Evolve abstract article image
Stack of gold plates fanning open around a turquoise light on dark blue, Evolve abstract article image

Insufficiency resulting from mutually exclusive definitions: The repercussive effect of dependent claims (T 0878/23)

  • 18th November 2025
In T 0878/23, the Board of Appeal ruled that mutually exclusive ranges in dependent claims constitute fatal insufficiency rather than a mere lack of clarity. This decision underscores the “repercussive effect” of claim dependencies, warning that internal contradictions can make an invention technically impossible to perform.
Ordered block of gold plates with three turquoise plates lifted out on dark blue, Evolve abstract article image
Ordered block of gold plates with three turquoise plates lifted out on dark blue, Evolve abstract article image

Evolve AI: Building AI tools for IP that are expert-led and pharma-specific

  • 2nd October 2025
We believe that the value of AI for our profession lies in developing highly specialised tools that build upon and incorporate domain-specific attorney expertise.
Sphere of gold hexagon plates with glowing turquoise seams on dark blue, Evolve abstract article image.
Sphere of gold hexagon plates with glowing turquoise seams on dark blue, Evolve abstract article image.

An “immunogenic composition” is not a vaccine (T 0070/23)

  • 8th August 2025
While G1/24 mandates consulting the description, T 0070/23 is a crucial reminder of its limits. The case shows how the Board of Appeal refused to let a description definition override the clear technical meaning of a product claim.
Single cut gold stone glowing turquoise at its heart on dark blue, Evolve abstract article image
Single cut gold stone glowing turquoise at its heart on dark blue, Evolve abstract article image

Do you need comparative data to patent an advanced therapy in Europe? Lessons from T 0827/23

  • 4th August 2025
Your biotech invention works, but can you prove it’s better? A recent EPO ruling on extracellular vesicles (T 0827/23) shows why the lack of comparative data can be fatal for a patent.
Twisting strand of gold beads with a turquoise section on dark blue, Evolve biotechnology image
Twisting strand of gold beads with a turquoise section on dark blue, Evolve biotechnology image

How to read a biotech patent

  • 23rd June 2025
Learn how to quickly search for and extract key information from biotech patent documents.
View more Insights

evolve® is a trading entity of Evolve Intellectual Property Limited. Evolve Intellectual Property Limited is regulated by the Intellectual Property Regulation Board (IPReg). Details of the UK professional rules can be found on the IPReg website

registered address: 49 Greek Street, London, England, W1D 4EG

website out of house

© 2026 All Rights Reserved

Keep in touch

  • Subscribe
  • Contact us
  • Cookie Notice
  • Complaints Procedure
  • Privacy notice
  • Subscribe
  • Contact us
  • Cookie Notice
  • Complaints Procedure
  • Privacy notice